County Bk Greenwood S C Com COYA 深 滬
已收盤 08-29 16:00:00 美东时间
6.56
-0.150
-2.24%
華盛通- 最 高6.88
- 今 開6.76
- 成交量 3.87万股
- 最 低 6.53
- 昨 收 6.71
- 總市值 1.10亿
- 52周最高 10.24
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.65
- 委 比 91.69%
- 總股本 1672.50万
- 歷史最高 10.6899
- 量 比 0.26
- 振 幅 5.22%
- 歷史最低 3.21
- 每 手 1
- 風險率 0.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Going On With Coya Therapeutics Stock?
Shares of Coya Therapeutics are trading higher Monday morning. The company provided an update regarding the development of a new treatment for Amyotrophic Lateral Sclerosis.
08-25 21:57
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $18 price target.
08-25 19:25
Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $14 price target.
08-13 22:28
Coya Therapeutics Q2 EPS $(0.36) Beats $(0.42) Estimate, Sales $163.616K Miss $940.000K Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by 13.46 percent. This is a 89.47 percent decrease over losses of $(0.19) per share from
08-12 20:05
沙特设立高端餐饮新规，拓展经济多元化路径
①沙特发布精致餐饮新规，明确设立专属营业许可和运营标准，推动高端餐饮纳入经济多元化发展路径； ②国际品牌与本土创业者共同布局，带动高端餐饮与供应链、商业地产等相关行业协同增长。
07-28 13:11
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target
D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $18 price target.
07-24 23:31
Lake Street Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $16
Lake Street analyst Chad Messer initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $16.
07-09 21:51
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $14 price target.
07-01 23:02
美股大行评级 | eToro Group获多家大行首予买入评级，甲骨文获多家机构上调目标价
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139116149842006017.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持PolyPid(PYPD)"买入"评级，目标价从11美元升至13美元</p> <p>• HC Wainwright & Co.：维持Vertical Aerosp
06-10 09:45
